Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Pembrolizumab / Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma

September 16, 2022 By Law Offices of Thomas J. Lamb, P.A.

The combination of pembrolizumab (Keytruda), and lenvatinib (Lenvima) demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma (MPM), according to results from the PEMMELA study (NCT04287829) presented at the International Association for the Study of Lung Cancer 2022 World … [Read more...]

Filed Under: Mesothelioma Tagged With: Keytruda, Lenvima, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Gallbladder Side Effects Related to Byetta and Other GLP-1 Receptor Agonists

September 13, 2022 By Law Offices of Thomas J. Lamb, P.A.

Cases of gallbladder side effects related to Byetta, Trulicity, Ozempic, and Adlyxin were reported in this August 2022 medical journal JAMA Internal Medicine article, “Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration”, which starts with the following: The … [Read more...]

Filed Under: Unsafe Drugs Tagged With: acute cholecystitis, Adlyxin, Byetta, gallbladder disease, Ozempic, Trulicity

The silent malignant mesothelioma epidemic: a call to action

September 9, 2022 By Law Offices of Thomas J. Lamb, P.A.

Malignant mesothelioma, recognised as a new disease in the 1950s, is almost exclusively caused by asbestos exposure and usually diagnosed decades after first exposure. The disease was initially restricted to asbestos workers, but diagnoses after non-occupational [ asbestos exposure ] continue to surge. Despite the acknowledgment by WHO and the … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, asbestos exposure, chrysotile asbestos, mesothelioma

Camp Lejeune Claims for Veterans and Family Diagnosed With Cancers

August 16, 2022 By Law Offices of Thomas J. Lamb, P.A.

The Camp Lejeune Justice Act of 2022 allows for claims to be filed against the US Government seeking legal compensation for veterans and their family members who have been diagnosed with serious medical conditions, diseases, and cancers that are associated with harmful chemicals that were in the Camp Lejeune contaminated water they used during 1953 … [Read more...]

Filed Under: Camp Lejeune Tagged With: Camp Lejeune claims, Camp Lejeune Claims Review, Camp Lejeune contaminated water, Camp Lejeune Justice Act, cancers, Marine Corps Air Station New River, Marine Corps Base Camp Lejeune, MCAS New River, North Carolina

Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US

August 8, 2022 By Law Offices of Thomas J. Lamb, P.A.

There is some new medical research about current population-based estimates of the incidence of breast implants-associated anaplastic large cell lymphoma (BIA-ALCL) -- more commonly called breast implants lymphoma cancer -- in the US, and the findings are rather alarming. From this recent news report, "ALCL Increasing Rapidly in US Women as … [Read more...]

Filed Under: Unsafe Medical Devices Tagged With: ALCL, BIA-ALCL, breast implant cancer, breast implant-associated anaplastic large cell lymphoma, breast implants BIA-ALCL

Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma

August 8, 2022 By Law Offices of Thomas J. Lamb, P.A.

The combination of galinpepimut-S and nivolumab (Opdivo) was found to extend survival in patients with malignant pleural mesothelioma who were either refractory to, or who had relapsed after, at least 1 line of standard therapy, according to updated data from a phase 1 trial (NCT04040231). The median overall survival (OS), which was calculated … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Second Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review

July 11, 2022 By Law Offices of Thomas J. Lamb, P.A.

Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumour with poor prognosis. To date, a multimodality treatment, including chemotherapy and surgery, with or without radiotherapy, is the gold standard therapy for selected patients with epithelioid and early-stage MPM. In this setting, the goal of surgery is to achieve the … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Copiktra May Increase Risks of Death and Serious Side Effects

July 11, 2022 By Law Offices of Thomas J. Lamb, P.A.

From this June 30, 2022, FDA Drug Safety Communication, “FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)”, we get the following: To evaluate the long-term safety of Copiktra, we required the drug manufacturer, Secura Bio, to submit the final 5-year survival results from the clinical … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Copiktra, deaths

A Case Report of Hypophosphatemia Leading to the Diagnosis of Mesothelioma

June 27, 2022 By Law Offices of Thomas J. Lamb, P.A.

Hypophosphatemia can be commonly encountered as an electrolyte imbalance and is defined as a value less than 0.8 mmol/l (2.5 mg/dl). It can be an incidental finding, but it is not uncommon to see it presenting with varied symptoms. It is good to have a clear diagnostic approach to this so adequate treatment can be instated. We present a … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma diagnosis

Xalkori Side Effects: Children Suffering Ocular Toxicity and Severe Visual Loss

June 24, 2022 By Law Offices of Thomas J. Lamb, P.A.

A June 14, 2022, European Pharmaceutical Review (EPR) article about the most recent meeting of EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reports a new drug safety issue involving Xalkori and vision loss found in clinical trials for pediatric patients treated with Xalkori. In relevant part from this EPR article about the EMA’s PRAC … [Read more...]

Filed Under: Unsafe Drugs Tagged With: vision loss, Xalkori

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 64
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.